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Abstract: 
Background:  
Ependymal tumors are glial tumors that commonly manifest in children and young 
adults. Their classification has remained entirely morphological until recently, and 
surgery and radiotherapy are the main treatment options, especially in adults. Here 
we sought to correlate DNA methylation profiles with clinical and pathological 
characteristics in the prospective cohort of the German Glioma Network. 
Methods:  
Tumors from 122 adult patients with myxopapillary ependymoma, ependymoma, 
anaplastic ependymoma, subependymoma or RELA fusion-positive ependymoma 
classified according to the World Heath Organization classification (WHO) 2016 were 
subjected to DNA methylation profiling using the Illumina HumanMethylation450 
BeadChip platform. Molecular data were correlated with histologic features and 
clinical characteristics. 
Results: 
At a median follow-up of 86.7 months, only 22 patients experienced progression 
(18.0%) and 13 patients (10.7%) died. Each tumor could be assigned to one of the 
previously defined molecular ependymoma subgroups. All histologic 
subependymomas corresponded to subependymoma (SE) DNA methylation 
subgroups, but the reverse was not true: 19 histologic ependymomas (WHO grade II) 
were allocated to molecular SE groups. Similarly, all histological myxopapillary 
ependymomas were assigned to the molecularly defined SP-MPE class, but this 
molecular subgroup additionally included 15 WHO grade II ependymomas by 
histology. Overall, WHO grade II ependymomas distributed into seven molecular 
subgroups. 
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Conclusions: 
Most adult patients with ependymoma show a favorable prognosis. Molecular 
classification may provide diagnostic and prognostic information beyond histology 
and facilitate patient stratification in future clinical trials. The prognostic significance 
of a subependymoma or myxopapillary ependymoma DNA methylation phenotype 
without according histology requires further study.  
 
 
 
 
Importance of the Study 
This study used DNA methylation profiling to molecularly classify 122 adult 
ependymal tumors from patients enrolled in the German Glioma Network. Each tumor 
was assigned to one of 8 previously defined molecular subgroups of ependymal 
tumors. Histologically diagnosed subependymomas (SE), myxopapillary 
ependymomas (SP-MPE) and supratentorial RELA fusion-positive ependymomas 
(ST-EPN-RELA) were unambiguously assigned to the respective molecular 
subgroups. Only one anaplastic ependymoma (WHO grade III) was classified into the 
subgroup spinal subependymoma (SP-SE), the remaining six anaplastic 
ependymomas were assigned to the molecular subgroup posterior fossa group B 
(PF-EPN-B). WHO grade II ependymomas distributed into seven molecular 
subgroups. Future studies need to determine whether molecular reclassification 
allows for treatment de-escalation, e.g. delay of radiotherapy, in subgroups of 
patients. DNA methylation profiling may provide diagnostic and prognostic 
information beyond histology and thus may facilitate patient stratification in future 
clinical trials. 
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Introduction 
 
The 2016 World Health Organization (WHO) classification of central nervous system 
tumors recognizes five distinct entities of ependymal tumors, subependymoma (WHO 
grade I), myxopapillary ependymoma (WHO grade I), ependymoma (WHO grade II), 
anaplastic ependymoma (WHO grade III), and RELA fusion-positive ependymoma 
(WHO grade II or III) 1. Recently nine molecular subgroups of ependymomas with key 
genetic und epigenetic characteristics across all age groups have been described 2. 
These were based on major central nervous system (CNS) compartments and 
histopathological and molecular findings: spine (SP), posterior fossa (PF) and 
supratentorial (ST) localization; subependymoma (SE), myxopapillary ependymoma 
(MPE), ependymoma (EPN), anaplastic ependymoma (EPN-A or -B: balanced 
genome or chromosomal instability), and ST-EPN-RELA, defined by RELA fusion 
transcript expression, as well as ST-EPN-YAP1, defined by the presence of YAP1 
fusion transcripts. 
The current histopathologic assessment has shortcomings, reliability and clinical 
significance of WHO grade II versus III have remained controversial, and histologic 
subtyping provides only limited guidance for clinical decision making. It might thus be 
worthwhile to supplement the current WHO classification by assessment of additional 
molecular markers or large-scale molecular profiling approaches to tailor 
management strategies and to avoid under-treatment as well as over-treatment of 
individual patients. Accordingly, we molecularly classified ependymomas of adults 
based on DNA methylation patterns determined by 450k DNA methylation arrays and 
related these data to age, tumor location and histology. Longer follow-up of our 
cohort will be required to derive robust conclusions on the prognostic value of this 
new classifier in adult ependymoma patients. 
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Patients and methods 
 
Molecular classification using DNA methylation profiling 
The present study evaluated clinical features and histopathologic findings in the 
ependymoma cohort of the German Glioma Network (GGN). The GGN is a 
prospective cohort study that enrolled adult patients with gliomas at 9 clinical centers 
in Germany from 2004-2012 (http://www.gliomnetzwerk.de). All patients gave written 
informed consent according to the research proposals approved by the Institutional 
Review Boards of the participating institutions. We included all patients with newly 
diagnosed tumors histologically diagnosed as subependymoma, myxopapillary 
ependymoma, ependymoma or anaplastic ependymoma. The histologic diagnosis 
was verified by central neuropathology review in all 122 patients based on the 2016 
WHO classification of tumors of the central nervous system 1.  
The Illumina Infinium HumanMethylation450 (450k) array was used to obtain 
genome-wide DNA for tumor samples and normal control tissues (Illumina, San 
Diego, CA, USA). Data were generated at the Genomics and Proteomics Core 
Facility of the German Cancer Research Center (DKFZ, Heidelberg, Germany). DNA 
methylation data was generated from either fresh-frozen (n=88) or formalin-fixed 
paraffin-embedded (FFPE) tissue samples (n=34). Tumor tissue originated from 
primary tumors (n=114) and from relapse tumors (n=8). For most fresh-frozen 
samples, >500 ng of DNA was used as input material; 250 ng DNA was used for 
most FFPE tissues. On-chip quality metrics of all samples were carefully controlled. 
Samples were also checked for unexpected genotype matches by pairwise 
comparison of the 65 genotyping probes included on the 450k array.  
All computational analyses were performed in R version 3.2.0 3. Raw signal 
intensities were obtained from IDAT-files using the minfi Bioconductor package 
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version1.14.0 4. Each sample was individually normalized by performing a 
background correction (shifting of the 5% percentile of negative control probe 
intensities to 0) and a dye-bias correction (scaling of the mean of normalization 
control probe intensities to 10,000) for both color channels. Subsequently, a 
correction for the type of material tissue (FFPE/frozen) was performed by fitting 
univariate, linear models to the log2-transformed intensity values (removeBatchEffect 
function, limma package version 3.24.15). The methylated and unmethylated signals 
were corrected individually. Beta-values were calculated from the retransformed 
intensities using an offset of 100 (as recommended by Illumina).  
The following filtering criteria were applied: removal of probes targeting the X and Y 
chromosomes (n=11,551), removal of probes containing a single nucleotide 
polymorphism (dbSNP132 Common) within five base pairs of and including the 
targeted CpG site (n=7,998), probes not mapping uniquely to the human reference 
genome (hg19) allowing for one mismatch (n=3,965), and probes not included on the 
new Illumina EPIC array (n=32,260). In total, 428,799 probes were kept for the 
analysis. 
Copy number variation (CNV) analysis from 450k methylation array data was 
performed using the conumee Bioconductor package version 1.3.0. Two sets of 50 
control samples displaying a balanced copy number profile from both male and 
female donors were used. For CNV analysis no previous normalization steps were 
performed. To predict molecular subgroups a Random Forest (RF) classifier was 
applied using 428,799 probes. This classifier was trained on a reference set of 2,801 
methylation profiles of brain tumors that were previously assigned to 91 molecular 
subgroups which cover almost all entities enlisted in the 2016 WHO classification of 
CNS tumors. For subgrouping of the 122 samples of this study the classification 
model including 91 molecular subgroups of brain tumors were used. The overall 
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prediction performance of this classifier was validated by a three-fold cross validation 
indicating a very high classification accuracy with a misclassification error rate of 
4.28% and a multiclass AUC of 0.9998 5,6. 
 
Statistical analyses 
Progression-free (PFS) and overall survival (OS) curves were estimated by the 
Kaplan-Meier method. PFS was calculated from the date of surgery to the date of 
progression. Patients without documented progression were censored at the last 
follow-up visit for PFS. OS was measured from the date of surgery to the date of 
death. Patients without confirmed death were censored for OS at last follow-up. 
Survival-related analyses were calculated using log-rank test. The association 
between molecular subgroups and clinical characteristics was analyzed by Chi-
square test and Fisher’s exact test and differences in age by Mann-Whitney U-test. 
All statistical tests were two-tailed, a p-value of 0.05 was set as statistically 
significant. All statistical analyses were performed using IBM SPSS Statistics Version 
24. Chi-square tests were used to calculate the independence of distinct 
chromosomal aberrations across molecular subgroups 2. Only gains and losses of 
whole chromosomes and chromosome arms were included into this analysis. 
Independences of CNV between molecular subgroups were calculated by Chi-square 
tests, p-values were computed by 100,000 Monte Carlo simulations. 
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Results 
 
Patient characteristics 
Table 1 summarizes relevant patient characteristics. Individual patient data are 
provided in Supplementary Table 1. Median age was 46 years (range: 18-80 years). 
The distribution of ages at diagnosis was relatively uniform across 10-year age 
groups between 30 and 70 years (15.6-18.9%), with a peak incidence in the 41-50 
year age group (28.7%) and fewer diagnoses in patients older than 70 years (4.9%). 
There was a male predominance (67.2%). Histologic diagnosis was WHO grade II 
ependymoma in the majority of cases (60.7%). WHO grade III (anaplastic) 
ependymomas were rarely diagnosed. The most commonly affected compartment 
was the spine (53.3%) followed by infratentorial (31.1%) and supratentorial (14.8%) 
locations. Metastatic dissemination at diagnosis was observed only once. Patients 
who received therapy beyond surgery at first-line treatment had myxopapillary 
ependymoma (n=1), ependymoma WHO grade II (n=7), anaplastic ependymoma 
WHO grade III (n=5) or RELA fusion-positive ependymoma (n=2). Each of these 
patients was treated with postoperative radiotherapy (RT) (Table 2, Supplementary 
Table 1). 
Median follow-up was 86.7 months, 22 patients experienced disease progression 
(18.0%), and 13 patients (10.7%) died, four patients with spinal, eight patients with 
intracranial and one patient with disseminated disease. Progression was seen in one 
of 23 patients (4.3%) with subependymoma, five of 14 patients (35.7%) with 
myxopapillary ependymoma, nine of 74 patients (12.2%) with ependymoma WHO 
grade II, four of seven patients (57.1%) with anaplastic ependymoma WHO grade III, 
and three of four patients with RELA fusion-positive tumors. At recurrence, 15 of 22 
patients (68.2%) had a second resection, followed by RT (n=5), CCNU chemotherapy 
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(CT) (n=1), or combined radiochemotherapy with temozolomide (n=1). Two of 22 
patients (9.1%) received RT alone and four patients received no further treatment 
(Table 2, Supplementary Table 1). PFS rate was 96.4% at 1 year (95% CI 93.0-100), 
90.4% at 3 years (95% CI 84.6-96.1), and 84.6% at 5 years (95% CI 77.3-81.8) for 
the entire patient cohort. OS rate was 99.1% at 1 year (95% CI 97.5-100), 97.1% at 3 
years (95% CI 93.9-100), and 95.9% at 5 years (95% CI 91.9-100). Deceased 
patients who did not die from ependymoma had other tumors (n=2) or cardiovascular 
or respiratory diseases (n=4). 
 
Molecular subgrouping 
Ependymal tumors of all 122 patients could be assigned to one of eight subgroups 
defined by distinct DNA methylation profiles: SP-SE (n=5; 4.1%), SP-MPE (n=29; 
23.8%), SP-EPN (n=32; 26.2%), PF-SE (n=24; 19.7%), PF-EPN-A (n=1; 0.8%), PF-
EPN-B (n=13; 10.7%), ST-SE (n=14; 11.5%) and ST-EPN-RELA (n=4; 3.3%) (Table 
3, Supplementary Figure 1, 2). No tumor was assigned to another non-ependymal 
tumor entity and no tumor was removed from the analysis. Patients with PF-EPN-B 
and ST-EPN-RELA as well as with SP-MPE and SP-EPN tumors were younger 
(median age 37-43 years), whereas patients in the subgroups SP-SE, PF-SE, and 
ST-SE tended to be older (median age 49-59 years) (Supplementary Figure 3). 
Figure 1 and Supplementary Table 2 illustrate how WHO 2016 diagnoses distribute 
into molecular subgroups and localization. All histologic subependymomas were 
assigned to the molecular SE groups. However, tumors assigned to the molecular 
subependymoma subgroups SP-SE, PF-SE and ST-SE also included 19 tumors 
histologically classified as ependymoma WHO grade II and one anaplastic 
ependymoma. All patients diagnosed with myxopapillary ependymoma were 
assigned to the molecularly defined SP-MPE subgroup. This molecular subgroup, 
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however, also included 15 WHO grade II ependymomas by histology. All patients 
assigned to SP-EPN, PF-EPN-A and PF-EPN-B corresponded to WHO grade II or III 
ependymomas (Figure 1, Supplementary Table 2).  
The potential clinical implications become apparent when considering group 
assignments by compartment. This yielded few apparent changes in the 
supratentorial compartment (Figure 1a). Among the posterior fossa tumors, 
subependymomas and anaplastic ependymomas showed a perfect match into the 
PF-SE and PF-EPN-B groups whereas WHO grade II ependymomas were 
heterogeneous by DNA methylation profiling and distributed to the prognostically 
different groups of PF-SE and PF-EPN-B (Figure 1b). The most extensive 
reassignments by molecular profiling occurred in the spinal compartment where a 
third of WHO grade II ependymomas were assigned to the SP-MPE molecular 
subgroup (Figure 1c). Representative histologic patterns of tumors, which were 
assigned to distinct molecular subgroups such as subependymoma, ependymoma 
WHO grade II, myxopapillary ependymoma, anaplastic ependymoma, and RELA 
fusion-positive ependymoma, are shown in Supplementary Figure 4. 
 
Chromosomal alterations show distinct patterns within molecular subgroups  
CNVs were calculated by analyzing combined intensity values of the methylation 
probes 7. Whole genome copy number profiles showed distinct chromosomal 
aberrations in terms of frequencies and specificity across the molecular ependymal 
subgroups (Figure 2, Supplementary Table 3). The single PF-EPN-PFA tumor was 
excluded here. Overall, molecular subependymoma (SE) group tumors within spinal, 
posterior fossa and supratentorial compartments showed infrequent CNVs. 
Surprisingly, SE commonly showed a loss of chromosome 19, most frequently within 
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PF-SE (79%), but also in ST-SE (50%) and SP-SE (40%) whereas genomic profiles 
were otherwise relatively flat. Another CNV frequently observed in SP-SE and PF-SE 
was partial chromosome 6 loss. 
Chromosome 6 loss was also frequently seen in PF-EPN-B tumors (61%). 
Additionally, PF-EPN-B tumors showed gains of chromosomes 15 (54%), 18 (54%), 
and 20 (54%), and losses of chromosome 17 (38%) which were the most frequent 
aberrations 2,8,9. Gain of chromosome 1q was seen in PF-EPN-B (23%) and in one 
ST-EPN-RELA.  
In SP-EPN and SP-MPE, most chromosomal gains and losses comprised large 
regions including whole chromosomes or chromosomal arms. SP-EPN showed 
deletions of chromosome arm 22q in more than 80% of tumors 10. Several CNVs 
were present in both SP-MPE and SP-EPN, the most common being loss of 22q in 
SP-EPN (90%) and SP-MPE (47%) tumors. 
Characteristic and significant CNVs for SP-SE were losses of chromosomes 18 
(20%) and 19 (40%), for SP-EPN gain of chromosome 12 (56%), loss of 13q (31%), 
and loss of 14q (31%). SP-MPE harbored gains of chromosome 16 (25%) and losses 
of chromosome 10 (25%). Exclusive chromosomal changes of ST-SE were losses of 
chromosomes 8 (29%) and 19 (50%). Characteristic and most frequent CNVs of ST-
EPN-RELA tumors were losses of chromosome 3 (75%), 9 (100%) and 11 (75%), as 
well as focal losses of chromosome 11q (75%), where the fusion-partner genes 
C11orf95 and RELA are localized 11,12. 
 
Molecular subgroups and survival 
Survival analyses showed differences in PFS and OS, although the low number of 
events allowed no conclusive statistical analysis between the eight molecular 
subgroups. Molecular subgroups associated with the poorest outcome were PF-EPN-
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B and ST-EPN-RELA, with 5-year PFS probability of 65.8% for PF-EPN-B and 25% 
for ST-EPN-RELA patients (Supplementary Figures 5, 6).  
The eight PF-EPN-B patients who had RT after initial surgery had a 5-years PFS rate 
of 72.9% (95% CI 40.6-100%) after a median follow-up of 7.3 years, as opposed to 
53.3% (95% CI 4.7-100%) after a median follow-up of 8.5 years for patients who did 
not. Four of eight patients in the RT group relapsed compared to three out of five 
patients without further therapy. All patients in the latter group initially had a gross 
total resection. In the RT group only four of eight patients had been gross totally 
resected. The age was roughly equal (median 34.5 years for patients with RT versus 
37 years for patients without treatment). PF-EPN-B patients had an OS rate at five 
years of around 100%, but survival probability dropped down to 37.5% at around 10 
years (Supplementary Figure 5). No significant differences in PFS (p=0.468; data not 
shown) and OS (p=0.083; data not shown) between WHO grade II and III tumors 
were observed in this subgroup. Notably, three of six PF-EPN-B patients with WHO 
grade III tumors, but none of seven patients with WHO grade II died.  
The number of ST-EPN-RELA tumors was small: three of four patients relapsed and 
died (Supplementary Figure 6). In contrast, SE tumors from the supratentorial and 
infratentorial compartments showed very good outcome. Importantly, two patients 
with ST-SE and one patient with PF-SE tumors died from other diseases, but not 
from their ependymomas (Supplementary Table 1).  
Patients with spinal molecular subgroups SP-EPN, SP-MPE and SP-SE had an 
excellent OS rate of 100% after 5 years. SP-MPE may relapse earlier and more often 
than the other spinal molecular subtypes, but longer follow-up is needed 
(Supplementary Figure 7).  
We investigated the molecular subgroup SP-MPE in more detail and compared 
patients with WHO grade I myxopapillary ependymoma (n=14) and WHO grade II 
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ependymoma (n=15), the latter representing patients whose tumors were molecularly 
reclassified as SP-MPE (Supplementary Table 4, Supplementary Figure 8). A 
comparison of clinical features revealed that patients with myxopapillary 
ependymomas WHO grade I were younger than patients with ependymomas WHO 
grade II (median 36 years versus 50 years, p=0.023). We observed a trend of SP-
MPE-assigned WHO grade II ependymomas to show tumor localization of the conus 
medullaris or filum terminale (Supplementary Table 1). None of the patients with SP-
MPE-assigned myxopapillary ependymomas died, but 2 patients with SP-MPE-
assigned WHO grade II ependymomas did, one patient for unknown reason while 
death of the other patient was unrelated to the spinal tumor (Supplementary Table 4). 
For SP-MPE myxopapillary ependymoma patients 5 progressions were observed as 
compared to only one progression in patients with SP-MPE-assigned WHO grade II 
ependymoma (Supplementary Figure 8). The two cohorts of SP-MPE patients 
showed a trend for better PFS of patients with myxopapillary ependymomas 
(p=0.071, n.s).  
The outcome comparison of the SP-EPN tumors (n=32), all of which had 
ependymoma WHO grade II histology, with tumors of the same histology that were 
assigned to the epigenetic SP-MPE subgroup (n=15) is presented in Supplementary 
Figure 9 and Supplementary Table 5. No relevant differences emerged. SP-EPN 
patients were younger by trend (median 42 years versus 50 years, p=0.123). Three 
patients died (n=1 SP-EPN and n=2 SP-MPE). 
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Discussion 
 
Ependymomas are rare brain tumors in adults. Half of these tumors occur in the 
spinal cord. Surgery and radiotherapy are the main treatment modalities 13. Gross 
total resection as safely feasible is recommended for all ependymal tumors whereas 
decisions against or for radiotherapy depend on residual tumor and histology based 
on the 2016 WHO classification 14.  
The present study is the first effort to characterize adult ependymomas beyond the 
WHO classification 2016, using a classifier based on DNA methylation profiling 
recently proposed for a largely pediatric population 2,6. The major strength of the 
present study is good clinical annotation regarding age, tumor location, treatment, 
and follow-up. Male patients were overrepresented in our cohort relative to data from 
larger registries 15. The low number of PFS and OS events, despite long follow-up, 
reflects the improved contemporary outcome for adult ependymoma patients. 
However, it precluded an in depth analysis of the potential prognostic value of the 
new molecular classifier. Similarly, no firm conclusions on the role of therapeutic 
measures beyond surgery can be derived. 
The vast majority of ependymomas in adults couldan readily be assigned to 7 of 9 
recently defined molecular subgroups (Table 3). ST-EPN-YAP1 tumors were not 
detected. ST-EPN-RELA, ST-EPN-YAP1 and PF-EPN-A are more common in or 
even restricted to children. That none of the tumors included in this study were 
assigned a non-ependymoma diagnosis by methylation profiling may be explained by 
the central pathology review within the German Glioma Network that took place prior 
to inclusion. 
The poor outcome of ST-EPN-RELA tumors observed in children may also be 
observed in adults (Table 3).  
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There was a weak trend in the small group of PF-EPN-B patients, who might show a 
better outcome when treated with radiotherapy compared to non-irradiated patients. 
However, due to the low number of patients, a recommendation of upfront radiation 
therapy cannot be concluded. If PF-EPN-B patients with incompletely resected tumors 
will benefit from upfront radiation therapy has to be evaluated in a randomized clinical 
trial in the future. 
The most important potential clinical implications of our study can be deduced from 
Figure 1. First, although all histologically defined subependymomas of WHO grade I 
were assigned to the molecular subependymoma subgroups SP-SE, PF-SE and ST-
SE, these molecular subgroups also included histologically defined ependymomas 
WHO grade II (n=19) and even a single case of anaplastic ependymoma WHO grade 
III. It is tempting to speculate, and supported by the preliminary data of this study, 
that among the histologically defined WHO grade II ependymomas, the molecular SE 
subgroup tumors have the best prognosis and patients with these tumors may be at 
risk of being overtreated with RT. The newly described chromosome 19 loss in 
subependymomas, especially in PF-SE, could potentially support the diagnostic 
process in the separation of PF-SE and PF-EPN-B, where this aberration was 
detected in less than 4% of cases (n=2) (Figure 2). 
Second, while all patients with histologically defined myxopapillary ependymoma 
WHO grade I were assigned to the molecularly defined SP-MPE subgroup, this 
molecular subgroup additionally included 15 spinal WHO grade II ependymomas by 
histology. The prognostic significance of this change in group allocation from 
histology to molecular subgroup is less clear although some institutions adopt 
different post-resection strategies of wait-and-see versus radiotherapy in patients 
with myxopapillary ependymoma versus WHO grade II ependymoma 14. Interestingly, 
gene expression profiling had previously indicated that WHO II grade ependymoma 
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and myxopapillary ependymoma are biologically distinct entities, although a subset of 
cases showed transcriptional profiles that could not be firmly assigned to either group 
10. The present study also suggests that a subset of spinal WHO grade II 
ependymomas is molecularly related to myxopapillary ependymomas by DNA 
methylation profiling. Interestingly, a previous study reported on the presence of both 
classic and myxopapillary histologic features in about 10% of lumbosacral ependymal 
tumors 16. Thus, histology and mRNA expression profiles may be ambiguous or not 
fully representative in a subset of spinal ependymal tumors, and additional DNA 
methylation profiling may thus be helpful in refining the classification of these cases. 
In this context, DNA methylation patterns of brain tumors are usually stable from the 
cell of origin until the development of a brain tumor and even at relapse 2,17., while 
gene expression changes may be more variable depending on microenvironmental 
influences as well as tumor cell differentiation and metabolism, as reported in spinal 
ependymomas 10. 
Third, we hypothesize that once targeted treatments for ependymal tumors become 
available, a molecular classifier will be superior to histology to enrich for clinical trial 
populations of patients with tumors sharing a similar cell of origin and biology. The 
verification of the RELA-fusion can support the diagnostic process of supratentorial 
ependymoma. 
Limitations of this study include the limited sample size per subgroup and the low 
number of PFS and OS events. Long-term follow up and independent cohort studies 
are required to confirm our assumption that molecular subgroup assignment of adult 
patients with ependymal tumors provides superior outcome description and 
enrichment for future clinical trials assessing therapeutic interventions. 
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FIGURE LEGENDS 
 
Figure 1. Reassignment of WHO 2016-based ependymoma diagnoses to 
molecular ependymoma subgroups based on DNA methylation profiles in the 
GGN cohort of adult patients with ependymomas stratified according to tumor 
location.  
A, Supratentorial ependymomas (ST); B, Posterior fossa ependymomas (PF); C, 
Spinal ependymomas (SP). 
 
Figure 2.  
Copy number variations across molecular subgroups of adult ependymal 
tumors.  
Summary of chromosomal imbalances showing distinct alterations within seven 
molecular subgroups of ependymal tumors. Copy number plots were generated 
based on DNA methylation, color code for losses (red), gains (green), and for 
balanced chromosomal profiles (gray). Results were plotted as frequencies at which 
these aberrations occurred within each molecular subgroup; significance is illustrated 
by p-values, which indicate distinct distributions of alterations across the molecular 
subgroups (chi-square test). 
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Table 1. Patient characteristics  
 N (%) 
All patients 122 
Age (years) 
Median  
Range 
 
46 
18 - 80 
Age classes 
< 31 years 
31 – 40 years 
41 – 50 years 
51 – 60 years 
61 – 70 years 
> 70 years 
 
20 (16.4) 
23 (18.9) 
35 (28.7) 
19 (15.6) 
19 (15.6) 
6 (4.9) 
Gender 
Male 
Female 
 
82 (67.2) 
40 (32.8) 
KPS at enrolment 
<70 
70-80 
90-100 
No data 
 
1 (1.0) 
41 (40.6) 
59 (58.4) 
21 
Histological diagnosis (ICD-O) 
Subependymoma (9383/1) 
Myxopapillary ependymoma (9394/1) 
Ependymoma (9391/3; 9393/3) 
Anaplastic ependymoma (9392/3) 
RELA fusion-positive (9396/3)  
 
23 (18.9) 
14 (11.5) 
74 (60.7) 
7 (5.7) 
4 (3.3) 
WHO 2016 tumor grade 
I 
II 
III 
 
37 (30.3) 
74 (60.7) 
11 (9.0) 
Tumor localization at diagnosis 
Intracranial - supratentorial 
Intracranial - infratentorial 
Spinal 
Disseminated 
 
18 (14.8) 
38 (31.1) 
65 (53.3) 
1 (0.8) 
Follow-up 
Median follow-up (months) 
Progression  
Dead 
Due to tumor progression 
Other reason 
Unknown 
 
86.7 
22 (18.0) 
13 (10.7) 
6 (4.9) 
6 (4.9) 
1 (0.8) 
 
KPS: Karnofsky Performance Score; WHO: World Health Organisation. 
 Table 2. Treatment regimes  
 N (%) 
All patients 122 
Initial tumor resection 
Partial  
Subtotal 
Gross total 
 
 
1 (0.8) 
23 (18.9) 
98 (80.3) 
 
Number of surgeries 
1 
> 1 
 
105 (86.1) 
17 (13.9) 
First-line therapy beyond surgery 
RT alone 
No therapy 
 
 
15 (12.3) 
107 (87.7) 
 
Therapy at first progression 
No therapy 
Re-resection 
Re-resection plus CCNU 
Re-resection plus RT 
Re-resection plus TMZ/RT  
RT  
22 
  4 (18.0) 
  8 (36.4) 
  1 (4.5) 
  5 (22.7) 
  1 (4.5) 
  2 (13.6) 
 
RT: radiotherapy; TMZ: temozolomide.
 Table 3. Patient characteristics based on ependymal tumor subgroups 
 SP-SE SP-MPE SP-EPN PF-SE PF-EPN-A PF-EPN-B ST-SE ST-EPN-RELA 
Number n (%) 5 (4.1) 29 (23.8) 32 (26.2) 24 (19.7) 1 (0.8) 13 (10.7) 14 (11.5) 4 (3.3) 
Age (years; median range) 59 (46-73) 43 (18-80) 42 (24-69) 54 (18-79) 42 (42-42) 37 (19-63) 49 (26-73) 37 (26-62) 
Gender         
  Male 2 (40.0) 20 (69.0) 17 (53.1) 23 (95.8) 1 (100.0) 6 (46.2) 11 (78.6) 2 (50.0) 
  Female 3 (60.0)   9 (31.0) 15 (46.9)   1 (4.2) 0 7 (53.8)   3 (21.4) 2 (50.0) 
KPS         
  <70 0   0   0   1 (4.2) 0 0 0 0 
  70-80 2 (66.7) 11 (52.4) 10 (41.7)   8 (33.3) 1 (100.0) 3 (25.0) 6 (46.2) 0 
  90-100 1 (33.3) 10 (47.6) 14 (58.3) 15 (62.5) 0 9 (75.0) 7 (53.8) 3 (100.0) 
  No data 2   8   8   1 1 1 
Surgery         
  Total 4 (80.0) 25 (86.2) 28 (87.5) 17 (70.8) 0 9 (69.2) 12 (85.7) 3 (75.0) 
  Subtotal 1 (20.0)   4 (13.8)   3 (9.4)   7 (29.2) 1 (100.0) 4 (30.8)   2 (14.3) 1 (25.0) 
  Partial 0   0   1 (3.1)   0 0 0   0 0 
Histology         
  Subependymoma 3 (60.0)   0   0   7 (29.2) 0 0 13 (92.9) 0 
  Myxopapillary ependymoma 0 14 (48.3)   0   0 0 0   0 0 
  Ependymoma 1 (20.0) 15 (51.7) 32 (100.0) 17 (70.8) 1 (100.0) 7 (53.8)   1 (7.1) 0 
  Anaplastic ependymoma 
  RELA fusion-positive 
1 (20.0) 
0 
  0 
  0  
  0 
  0 
  0 
  0 
0 
0 
6 (46.2) 
0 
  0 
  0 
4 (100.0) 
4 (100.0) 
WHO 2016 grade         
  I 3 (60.0) 14 (48.3)   0   7 (29.2) 0 0 13 (92.9) 0 
  II 1 (20.0) 15 (51.7) 32 (100.0) 17 (70.8) 1 (100.0) 7 (53.8)   1 (7.1) 0 
  III 1 (20.0)   0   0   0 0 6 (46.2)   0 4 (100.0) 
Localization         
  Intracranial – supratentorial 0   0   0   0 0 0 14 (100.0) 4 (100.0) 
  Intracranial – infratentorial 1 (20.0)   0   0 24 (100.0) 1 (100.0) 12 (92.3)   0 0 
  Spinal 4 (80.0) 29 (100.0) 32 (100.0)   0 0 0   0 0 
  Disseminated 0   0   0   0 0 1 (7.7)   0 0 
First-line therapy beyond surgery         
  RT alone (including cyber knife) 0   2 (6.9)   1 (3.1)   2 (8.3) 0 8 (61.5)   0 2 (50.0) 
  None 5 (100.0) 27 (93.1) 31 (96.9) 22 (91.7) 1 (100.0%) 5 (38.5) 14 (100.0) 2 (50.0) 
Progression         
  Events, n (%) 0 6 (20.7) 2 (6.3) 3 (12.5) 0 7 (53.8) 1 (7.1) 3 (75.0) 
Death         
    Events, n (%) 0  2 (6.9) 1 (3.1) 2 (8.3) 0  3 (23.1) 2 (14.3) 3 (75.0) 
KPS: Karnofsky Performance Score; WHO: World Health Organisation 
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Supplementary Table 1.  
Individual patient characteristics. 
 
Patient Age Gender Histology WHO 
grade 
Molecular 
subgroup 
Tumor 
localisation 
Extent of 
resection 
Adjuvant 
therapy 
PFS 
(months) 
Salvage 
therapy 
OS 
(months) 
 
 
1 42 m ependymoma II PF-EPN-A intracranial - 
infratentorial 
subtotal none 108.2  108.2 
2§§ 30 f anaplastic 
ependymoma * 
III PF-EPN-B disseminated, 
brain stem 
total none 8.5+ re-resection 100.2++§ 
3 19 f ependymoma II PF-EPN-B intracranial - 
infratentorial 
total none 60.8+ re-resection 
plus RT 
120.8 
4 24 m ependymoma II PF-EPN-B intracranial - 
infratentorial 
total RT 62.1  62.1 
5 28 f ependymoma II PF-EPN-B intracranial - 
infratentorial 
subtotal RT 15.4+ re-resection 167.1 
6 37 m ependymoma II PF-EPN-B intracranial - 
infratentorial 
total none 16.8  16.8 
7 41 f ependymoma II PF-EPN-B intracranial - 
infratentorial 
total RT 83.1  83.1 
8 44 m ependymoma II PF-EPN-B intracranial - 
infratentorial 
total none 52.2+ re-resection 
plus RT 
101.9 
9 51 f ependymoma II PF-EPN-B intracranial - 
infratentorial 
total none 72.0  72.0 
10 27 f anaplastic 
ependymoma 
III PF-EPN-B intracranial - 
infratentorial 
total RT 19.9  19.9 
11 54 m anaplastic 
ependymoma 
III PF-EPN-B intracranial - 
infratentorial 
total RT 66.9  66.9++§ 
12§§ 55 m anaplastic 
ependymoma 
III PF-EPN-B intracranial - 
infratentorial 
subtotal RT 30.4+ re-resection 87.5 
13 63 f anaplastic 
ependymoma 
III PF-EPN-B intracranial - 
infratentorial 
subtotal RT 67.9+ re-resection 
plus RT 
117.8 
3  
14 25 m anaplastic 
ependymoma 
III PF-EPN-B intracranial - 
infratentorial  
subtotal RT 66.7+ re-resection 
plus CCNU 
128.4++ 
15 46 m subependymoma I PF-SE intracranial - 
infratentorial 
total none 81.5  81.5 
16 48 m subependymoma I PF-SE intracranial - 
infratentorial 
total none 20.5  20.5 
17 52 m subependymoma I PF-SE intracranial - 
infratentorial 
subtotal none 13.1  13.1 
18 54 m subependymoma I PF-SE intracranial - 
infratentorial 
total none 116.5  116.5 
19 56 m subependymoma I PF-SE intracranial - 
infratentorial 
total none 111.3  111.3 
20 67 m subependymoma I PF-SE intracranial - 
infratentorial 
total none 33.7+ - 33.7++ 
21 35 m subependymoma I PF-SE intracranial - 
infratentorial 
total none 15.9  15.9 
22 18 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 0.1  0.1 
23 38 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 84.3  84.3 
24 40 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 57.9  57.9 
25 40 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 56.5  56.5 
26 45 m ependymoma II PF-SE intracranial - 
infratentorial 
subtotal none 24.3  24.3 
27 47 f ependymoma II PF-SE intracranial - 
infratentorial 
total none 82.2  82.2 
28 52 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 38.9  38.9 
29 54 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 38.7  38.7 
30 60 m ependymoma II PF-SE intracranial - 
infratentorial 
subtotal RT 89.3  89.3 
4  
31 62 m ependymoma II PF-SE intracranial - 
infratentorial 
subtotal none 71.9  71.9 
32 65 m ependymoma II PF-SE intracranial - 
infratentorial 
subtotal none 46.6+ RT 49.8 
33 65 m ependymoma II PF-SE intracranial - 
infratentorial 
subtotal none 114.8  114.8 
34 66 m ependymoma II PF-SE intracranial - 
infratentorial 
subtotal RT 41.6+ RT 121.4 
35 67 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 86.7  86.7 
36 70 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 0.6  0.6++§ 
37 71 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 82.6  82.6 
38 79 m ependymoma II PF-SE intracranial - 
infratentorial 
total none 79.6  79.6 
39 24 f ependymoma II SP-EPN spinal subtotal none 36.5  36.5 
40 29 f ependymoma II SP-EPN spinal total none 35.1  35.1 
41 30 f ependymoma II SP-EPN spinal total none 141.2  141.2 
42 31 m ependymoma II SP-EPN spinal total RT 53.4+ - 90.5 
43 32 f ependymoma II SP-EPN spinal total none 85.3  85.3 
44 32 m ependymoma II SP-EPN spinal total none 47.4  47.4 
45 32 m ependymoma II SP-EPN spinal total none 105.9  105.9 
46 34 m ependymoma II SP-EPN spinal subtotal none 30.2  30.2 
47 36 f ependymoma II SP-EPN spinal total none 36.8  36.8 
48 36 f ependymoma II SP-EPN spinal total none 14.9  14.9 
49 38 m ependymoma II SP-EPN spinal total none 99.7  99.7 
50 39 m ependymoma II SP-EPN spinal total none 33.3  33.3 
51 39 m ependymoma II SP-EPN spinal total none 122.1  122.1 
52 40 m ependymoma II SP-EPN spinal total none 0.1  0.1 
53 41 m ependymoma II SP-EPN spinal total none 71.8  71.8 
5  
54 42 f ependymoma II SP-EPN spinal total none 58.1  58.1 
55 42 f ependymoma II SP-EPN spinal total none 65.6  65.6 
56 43 f ependymoma II SP-EPN spinal total none 180.5  180.5 
57 44 f ependymoma II SP-EPN spinal total none 109.5  109.5 
58 45 m ependymoma II SP-EPN spinal total none 95.8  95.8 
59 46 f ependymoma II SP-EPN spinal total none 15.8  15.8 
60 46 m ependymoma II SP-EPN spinal subtotal none 59.5  59.5 
61 49 m ependymoma II SP-EPN spinal total none 98.5+ - 98.5++ 
62 49 f ependymoma II SP-EPN spinal total none 117.1  117.1 
63 49 m ependymoma II SP-EPN spinal total none 131.7  131.7 
64 50 m ependymoma II SP-EPN spinal total none 0.2  0.2 
65 53 f ependymoma II SP-EPN spinal total none 32.3  32.3 
66 60 f ependymoma II SP-EPN spinal total none 5.3  5.3 
67 67 m ependymoma II SP-EPN spinal total none 136.4  136.4 
68 69 f ependymoma II SP-EPN spinal partial none 43.5  43.5 
69 69 m ependymoma II SP-EPN spinal total none 16.4  16.4 
70 69 m ependymoma II SP-EPN spinal total none 73.3  73.3 
71 23 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 47.0+ RT 65.0 
72§§ 26 m myxopapillary 
ependymoma * 
I SP-MPE spinal subtotal none 34.8+ re-resection 199.7 
73 27 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 142.6  142.6 
74 28 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 105.6  105.6 
75 29 f myxopapillary 
ependymoma 
I SP-MPE spinal total RT 95.6  95.6 
76 34 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 68.4  68.4 
77§§ 38 m myxopapillary 
ependymoma * 
I SP-MPE spinal subtotal none 13.4+ re-resection 124.2 
6  
78 43 f myxopapillary 
ependymoma 
I SP-MPE spinal total none 125.4  125.4 
79 44 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 0.3  0.3 
80 49 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 149.7  149.7 
81 50 m myxopapillary 
ependymoma 
I SP-MPE spinal total none 75.3+ re-resection 
plus RT 
114.5 
82 67 f myxopapillary 
ependymoma 
I SP-MPE spinal total none 83.3  83.3 
83 29 m ependymoma II SP-MPE spinal** total none 62.8  62.8 
84 31 f ependymoma II SP-MPE spinal** total none 110.8  110.8 
85 39 f ependymoma II SP-MPE spinal** total none 112.9  112.9 
86 39 m ependymoma II SP-MPE spinal** total none 82.3  82.3 
87 41 m ependymoma II SP-MPE spinal** total none 109.4  109.4 
88 41 m ependymoma II SP-MPE spinal** subtotal none 22.8  22.8 
89 50 m ependymoma II SP-MPE spinal** total none 129.5  129.5 
90 50 f ependymoma II SP-MPE spinal** total none 100.1  100.1 
91 52 m ependymoma II SP-MPE spinal** total none 47.6  47.6 
92 54 m ependymoma II SP-MPE spinal** total none 124.7  124.7 
93 57 f ependymoma II SP-MPE spinal** total none 54.0  54.0 
94 58 m myxopapillary 
ependymoma 
I SP-MPE spinal** total none 105.4  105.4 
95§§ 59 f ependymoma * II SP-MPE spinal** total none 36.0+ re-resection 111.1 
96 62 f ependymoma II SP-MPE spinal** total none 100.1  100.1 
97 71 m ependymoma II SP-MPE spinal total RT 78.4  78.4++ 
98 80 m ependymoma II SP-MPE spinal** total none 79.9  79.9++§ 
99§§ 18 m myxopapillary 
ependymoma * 
I SP-MPE spinal subtotal none 91.6+ re-resection 222.0 
100 73 m subependymoma I SP-SE intracranial - 
infratentorial 
total none 116.4  116.4 
7  
101 46 f subependymoma I SP-SE spinal total none 115.3  115.3 
102 65 m subependymoma I SP-SE spinal subtotal none 4.3  4.3 
103 48 f ependymoma II SP-SE spinal total none 47.3  47.3 
104 59 f anaplastic 
ependymoma 
III SP-SE spinal total none 31.1  31.1 
105§§ 28 f RELA fusion-
positive * 
III ST-EPN-
RELA 
intracranial - 
supratentorial 
total none 11.5+ re-resection 
plus RT 
185.9++ 
106 26 m RELA fusion-
positive 
III ST-EPN-
RELA 
intracranial - 
supratentorial 
total none 6.8+ re-resection 122.9++ 
107 46 m RELA fusion-
positive 
III ST-EPN-
RELA 
intracranial - 
supratentorial 
subtotal RT 4.4+ re-resection 
plus RT/TMZ 
18.2++ 
108 62 f RELA fusion-
positive 
III ST-EPN-
RELA 
intracranial - 
supratentorial 
total RT 107.2  107.2 
109 26 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 4.7  4.7 
110 34 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 18.1  18.1 
111 41 f subependymoma I ST-SE intracranial - 
supratentorial 
total none 104.1  104.1 
112 45 f subependymoma I ST-SE intracranial - 
supratentorial 
total none 24.3  24.3 
113 46 m subependymoma I ST-SE intracranial - 
supratentorial 
subtotal none 136.8  136.8 
114 48 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 116.9  116.9 
115 50 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 109.3  109.3 
116 54 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 0.2  0.2 
117 56 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 4.0  4.0 
118 64 m subependymoma I ST-SE intracranial - 
supratentorial 
subtotal none 121.7  121.7 
119 64 f subependymoma I ST-SE intracranial - total none 104.3  104.3 
8  
supratentorial 
120 73 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 59.0  59.0++§ 
121 32 m subependymoma I ST-SE intracranial - 
supratentorial 
total none 0.0  0.0 
122§§ 63 m ependymoma * II ST-SE intracranial - 
supratentorial 
total none 97.7+ - 170.7++§ 
m, male; f, female; RT, radiotherapy; PFS, progression-free survival; OS, overall survival; * histological diagnosis was verified by 
central neuropathological review from recurrent tumor tissue (n=7); + indicates patients with progressive disease; ++ indicates patients 
who are deceased ; § patient deceased but not because of ependymal tumor progression; ** located in the conus medullaris, cauda 
equina, or filum terminale (data were only assessed for patients diagnosed histopathologically with “ependymoma” and molecularly 
with “SP-MPE”). §§ indicates cases where recurrent tumor tissue was used for DNA methylation profiles. 
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Supplementary Table 2.  
Histological association with molecular subgroup and tumor localization. 
 
Histological diagnosis Number (Localization) Molecular Subgroup 
Subependymoma 
WHO-grade I 
n=23  
n=2   (spinal)   
n=1   (infratentorial) 
n=7   (infratentotrial)   
n=13 (supratentorial)   
SP-SE  
SP-SE  
PF-SE 
ST-SE 
Myxopapillary ependymoma 
WHO-grade I 
n=14 
 
n=14 (spinal) SP-MPE 
Ependymoma 
WHO-grade II 
n=74 
 
n=1   (supratentorial) 
n=1   (spinal) 
n=15 (spinal) 
n=32 (spinal) 
n=17 (infratentorial) 
n=7   (infratentorial) 
n=1   (infratentorial) 
 
ST-SE 
SP-SE 
SP-MPE 
SP-EPN 
PF-SE 
PF-EPN-B 
PF-EPN-A 
Anaplastic ependymoma 
WHO-grade III 
n=7 
 
n=1   (brain stem, disseminated) 
n=5   (infratentorial) 
n=1   (spinal) 
 
PF-EPN-B 
PF-EPN-B 
SP-SE 
 
RELA-fusion positive 
WHO-grade III 
n=4 
 
n=4   (supratentorial) ST-EPN-RELA 
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Supplementary Table 3.  
Frequency of copy number variations. 
 
Molecular  
Subgroups 
Chromosome gains Chromosome losses 
SP-SE - 6 (20%), 18 (20%), 19 (40%) 
SP-MPE 16 (25%) 10 (25%), 22q del. (47%) 
SP-EPN 12 (56%) 13q (31%), 14q (31%), 22q del. (90%) 
   
PF-SE - 6 (17%), 19 (79%) 
PF-EPN-B 1q (23%),  15q (54%), 18 (54%), 20 (54%) 6 (61%), 17 (38%) 
   
ST-SE - 8 (29%), 19 (50%) 
ST-EPN-RELA 1q (25%) 3 (75%), 9 (100%), 11 (75%), focal loss 11q (75%) 
   
 
del., deletion; only selected characteristic copy number variations were included in this table.   
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Supplementary Table 4. (related to Supplementary Figure 8) 
Clinical features of molecularly classified spinal myxopapillary ependymoma (SP-MPE) by histology: 
histologicalmyxopapillary ependymoma (WHO grade I) versus histological spinal ependymoma (WHO grade II). 
 
Molecular Subgroup 
Spinal Myxopapillary Ependymoma 
(SP-MPE) N=29 
 
--------------------------------------------------- 
Clinical information 
 
Histological diagnosis 
Myxopapillary Ependymoma  
(WHO grade I) 
n=14 
Histological diagnosis 
Ependymoma  
(WHO grade II) 
N=15 
P-value 
Age, median (range) 36 year (18-67years) 50 years (29-80 years) 0.023 
Male, n (%) 11/14 (78.6%) 9/15 (60.0%) 0.427 
Gross total resection, n (%) 11/14 (78.6%) 14/15 (93.3%) 0.330 
KPS <90, n (%) 4/8 (50%) 7/13 (53.8%) 1.0 
First-line  
  RT 
 
1/14 (7.1%) 
 
1/15 (6.7%) 
 
1.0 
Progress 5/14 (35.7%) 1/15 (6.7%) 0.08 
Salvage 
  Re-resection 
  Re-resection + RT 
  RT 
 
3 
1 
1 
 
1 
0 
0 
 
n.s. 
n.s. 
n.s 
Death 0/14 (0%) 2*/15 (13.3%) 0.483 
 
P-values calculated by Fisher’s exact test. *Cause of death of one patient was not brain tumor-related, for the other one unknown.  
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Supplementary Table 5 (related to Supplementary Figure 9). 
Clinical features of histological spinal WHO grade II tumors, either molecularly classified as myxopapillary ependymoma (SP-
MPE; n=15) or as spinal ependymoma (SP-EPN; n=32). 
 
Histological diagnosis 
Spinal WHO grade II ependymomas  
N=47 
 
-------------------------------- 
Clinical information 
 
Molecular Subgroup 
Spinal Myxopapillary Ependymoma  
(SP-MPE) 
only WHO grade II tumors 
n=15 
Molecular Subgroup 
Spinal Ependymoma   
(SP-EPN) 
only WHO grade II tumors 
n=32 
P-value 
Age, median (range) 50 years (29-80) 42 years (24-69) 0.123 
Male, n (%) 9/15 (60.0%) 17/32 (53.1%) 0.659 
Gross total resection 14/15 (93.3%) 28/32 (87.5%) 1.0 
KPS <90%  7/13 (53.8%) 10/24 (41.7%) 0.478 
First-line  
  RT 
 
1/15 (6.7%) 
 
1/32 (3.1%) 
 
0.541 
Progress 1/15 (6.7%) 2/32 (6.3%) 1.0 
Salvage 
 Re-resection 
 None 
 
1 
0 
 
0 
0 
 
Death 2*/15 (13.3%) 1/32 (3.1%) 0.235 
P-values calculated by Fisher’s exact test. *Cause of death of one patient was not brain tumor related, for the other one unknown.  
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Supplementary Figure 1: Distribution of molecular subgroups of adult 
ependymal tumors of the German Glioma Network cohort by DNA 
methylation analysis. 
Supplementary Figure 2:
Supplementary Figure 2:
Unsupervised 2D representation of pairwise sample correlations by t-distributed 
stochastic neighbor embedding (t-SNE) dimensionality reduction. Individual samples 
(n=122) are color coded in the respective class color. Samples of the same class form 
dense aggregations and are mostly clearly separated from other classes. Other classes 
(molecular subtypes) like EPN-PF-SE, EPN-PFA, EPN-PFB show a closer aggregation, 
indicating a higher inter-class relation.
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Supplementary Figure 3: Molecular subgroups by age distribution. 
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Supplementary Figure 4:
Supplementary Figure 4: Histological versus molecular group assignment.
Histology of cases assigned by methylation profiling to the methylation group SE
(subependymoma) varies (a-d).
(a) Characteristic features such as clustered low-proliferative cells at low density lead
to the WHO diagnosis of subependymoma (WHO grade I). Other cases of this
methylation group contained histologically defined ependymoma (WHO grade II) (b)
and even a case of high cellularity and brisk mitotic (c, arrows) and proliferative activity
(d, KI-67 immunohistochemistry);
Representative histology examples (e – f) show a spinal case that had predominant
clear cell features but very focal perivascular mucoid deposits (f). This case was
diagnosed as ependymoma WHO grade II although it showed local features of
myxopapillary ependymoma, and corresponded to the methylation subgroup of SP-
MPE (myxopapillary ependymoma); (g) anaplastic ependymoma with RELA fusion
displaying strong nuclear accumulation of p65-RelA protein (immunohistochemistry;
Pietsch et al, 2014 [7]);
(h) shows the only posterior fossa tumor defined by methylation classifier as EPN-PFA
tumor. Histologically, it showed advanced differentiation and very low mitotic activity,
and was diagnosed as ependymoma WHO grade II.
Supplementary Figure 5: Posterior fossa Subgroups
Supplementary Figure 5: Inferior outcome with PF-EPN-B tumors.
PFS (a) and OS (b) for patients with PF-SE and PF-EPN-B tumors.
a
b
Supplementary Figure 6: Supratentorial Subgroups
Supplementary Figure 6: Inferior outcome with ST-EPN-RELA tumors.
PFS (a) and OS (b) for patients with ST-SE and ST-EPN-RELA tumors.
a
b
Supplementary Figure 7: Spinal Subgroups
Supplementary Figure 7: Outcome of spinal ependymomas by molecular subgroup.
PFS (a) and OS (b) for patients with SP-SE, SP-MPE and SP-EPN tumors.
a
b
Supplementary Figure 8:
Supplementary Figure 8: Outcome of SP-MPE tumors by histology. PFS (a) and OS (b) for 
patients with histological myxopapillary ependymoma WHO grade I versus ependymoma 
WHO grade II
a
b
Supplementary Figure 9:
Supplementary Figure 9. Outcome of histological spinal WHO grade II ependymoma by 
molecular assignment. PFS (a) and OS (b) for SP-MPE versus SP-EPN tumors.
a
b
